<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347840</url>
  </required_header>
  <id_info>
    <org_study_id>CI-10-0004</org_study_id>
    <nct_id>NCT01347840</nct_id>
  </id_info>
  <brief_title>Metabolic Factors of Outcomes From Gastric Bypass Surgery</brief_title>
  <acronym>Cassini</acronym>
  <official_title>Metabolic Factors of Outcomes From Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon Endo-Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether the metabolic, endocrine and energetic
      response to short term caloric restriction are factors in weight loss in subjects having
      gastric bypass (GB) surgery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated for business reasons.
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Excess Weight Loss</measure>
    <time_frame>16 months</time_frame>
    <description>Calculated as the difference between the baseline weight and weight at endpoint divided by the difference between baseline weight and ideal body weight using the medium frame range in the Metropolitan Tables for Life Insurance, 1983 x 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resting Energy Expenditure</measure>
    <time_frame>16 months</time_frame>
    <description>Energy expended at rest (minimal movement) and during fasting. Resting Energy Expenditure can be expressed per minute or per hour or per day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve of Ghrelin and GLP-1</measure>
    <time_frame>16 months</time_frame>
    <description>These variables will measure the combined effects of hormone concentration and duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of Timed Gastrointestinal Hormones (Insulin, GIP, Pancreatic Polypeptide, Peptide YY (PYY), Amylin, Glucagon, Pro-Insulin, C-Peptide)</measure>
    <time_frame>16 months</time_frame>
    <description>These variables will measure the combined effects of hormone concentration and duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin and Lectin</measure>
    <time_frame>16 months</time_frame>
    <description>These laboratory values will be collected at Visit 3, Visit 5, Visit 6, and Visit 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Questionnaires</measure>
    <time_frame>16 months</time_frame>
    <description>The subscales and total scores as set out in the scoring algorithms for Food Craving Inventory-II and Questionnaire on Craving for Sweet and Rich Foods will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of Glucose</measure>
    <time_frame>16 months</time_frame>
    <description>This variable will measure the combined effects of glucose concentration and duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c and Lipid Panel</measure>
    <time_frame>16 months</time_frame>
    <description>These laboratory values will be collected at Screening, Visit 8, and Visit 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>16 Months</time_frame>
    <description>Will be calculated at Screening, Visit 3, Visit 5, Visit 6, Visit 8, and Visit 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Weight Loss</measure>
    <time_frame>16 Months</time_frame>
    <description>(Weight at Baseline - Weight at Each Visit) divided by the (Weight at Baseline).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects having gastric bypass (GB) surgery within 4 months of screening visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects satisfying the following criteria will be considered the screening population and
        will be eligible for enrollment in this study:

          1. Subject is willing to give consent and comply with evaluation and treatment schedule

          2. 18 to 65 years of age (inclusive) on date of signing the ICD

          3. Subject is scheduled to have non-revisional GB surgery between 2 weeks to 4 months
             after signing the ICD

          4. Able to read, understand, and follow study procedures as outlined in the ICD.

        Exclusion Criteria:

        Subjects meeting the following criteria will not be eligible for enrollment:

          1. Unable or unwilling to attend follow-up visits and examinations

          2. Women who are pregnant, nursing at the time of screening, or planning to become
             pregnant within one year of the GB surgery

          3. Clinically active cardiac, renal, hepatic or GI disorders

          4. Screening laboratory tests with any of the following:

               -  alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] ≥ 4 times
                  upper limit of normal (ULN) according to VAMC normal ranges

               -  AST:ALT &gt; 2:1 according to VAMC normal ranges

               -  Serum Creatinine ≥ 1.5 times ULN according to VAMC normal ranges

               -  Blood Urea Nitrogen (BUN) ≥ 1.5 times ULN according to VAMC normal ranges

               -  Positive test results for Hepatitis A, B or C

          5. Clinically active thyroid or lipid disorders:

               -  Thyroid-stimulating hormone (TSH) flagged as critical value (per VAMC lab normal
                  ranges)

               -  Triglycerides &gt; 400 mg/dL

          6. Anemia:

               -  Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean
                  corpuscular hemoglobin concentration (MCHC) outside normal VAMC range; or

               -  Hematocrit &lt; 36%

          7. Uncontrolled hypertension which required a medication regimen adjustment during the 3
             months prior to screening

          8. Currently prescribed or taking atypical antipsychotic medication

          9. Currently prescribed or taking chronic, long-term, oral corticosteroid medication

         10. Diabetes requiring a drug regimen which includes insulin treatment at the time of
             screening

         11. Unwilling or unable to refrain from having a procedure or surgery which involves the
             removal of skin tissue which could result in weight loss

         12. Any medical condition or finding for which the PI used medical discretion to determine
             the subject should be excluded; or

         13. Participation in any other investigational device or drug study (non survey based
             trial) during the course of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David D'Alessio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Affairs Medical Center, Cincinnati, OH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>April 19, 2012</results_first_submitted>
  <results_first_submitted_qc>April 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2012</results_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity Gastric Bypass Roux en Y</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">1 subject enrolled but withdrew consent</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Excess Weight Loss</title>
        <description>Calculated as the difference between the baseline weight and weight at endpoint divided by the difference between baseline weight and ideal body weight using the medium frame range in the Metropolitan Tables for Life Insurance, 1983 x 100.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Excess Weight Loss</title>
          <description>Calculated as the difference between the baseline weight and weight at endpoint divided by the difference between baseline weight and ideal body weight using the medium frame range in the Metropolitan Tables for Life Insurance, 1983 x 100.</description>
          <units>percentage of excess weight</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Resting Energy Expenditure</title>
        <description>Energy expended at rest (minimal movement) and during fasting. Resting Energy Expenditure can be expressed per minute or per hour or per day.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Energy Expenditure</title>
          <description>Energy expended at rest (minimal movement) and during fasting. Resting Energy Expenditure can be expressed per minute or per hour or per day.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve of Ghrelin and GLP-1</title>
        <description>These variables will measure the combined effects of hormone concentration and duration.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of Ghrelin and GLP-1</title>
          <description>These variables will measure the combined effects of hormone concentration and duration.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve of Timed Gastrointestinal Hormones (Insulin, GIP, Pancreatic Polypeptide, Peptide YY (PYY), Amylin, Glucagon, Pro-Insulin, C-Peptide)</title>
        <description>These variables will measure the combined effects of hormone concentration and duration.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of Timed Gastrointestinal Hormones (Insulin, GIP, Pancreatic Polypeptide, Peptide YY (PYY), Amylin, Glucagon, Pro-Insulin, C-Peptide)</title>
          <description>These variables will measure the combined effects of hormone concentration and duration.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin and Lectin</title>
        <description>These laboratory values will be collected at Visit 3, Visit 5, Visit 6, and Visit 10.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin and Lectin</title>
          <description>These laboratory values will be collected at Visit 3, Visit 5, Visit 6, and Visit 10.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Questionnaires</title>
        <description>The subscales and total scores as set out in the scoring algorithms for Food Craving Inventory-II and Questionnaire on Craving for Sweet and Rich Foods will be presented.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Questionnaires</title>
          <description>The subscales and total scores as set out in the scoring algorithms for Food Craving Inventory-II and Questionnaire on Craving for Sweet and Rich Foods will be presented.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve of Glucose</title>
        <description>This variable will measure the combined effects of glucose concentration and duration.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of Glucose</title>
          <description>This variable will measure the combined effects of glucose concentration and duration.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c and Lipid Panel</title>
        <description>These laboratory values will be collected at Screening, Visit 8, and Visit 10.</description>
        <time_frame>16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c and Lipid Panel</title>
          <description>These laboratory values will be collected at Screening, Visit 8, and Visit 10.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Will be calculated at Screening, Visit 3, Visit 5, Visit 6, Visit 8, and Visit 10.</description>
        <time_frame>16 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Will be calculated at Screening, Visit 3, Visit 5, Visit 6, Visit 8, and Visit 10.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Weight Loss</title>
        <description>(Weight at Baseline – Weight at Each Visit) divided by the (Weight at Baseline).</description>
        <time_frame>16 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Loss</title>
          <description>(Weight at Baseline – Weight at Each Visit) divided by the (Weight at Baseline).</description>
          <units>percentage of weight loss</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial termination due to business needs. One subject enrolled and withdrew consent. Zero subjects completed study. No subject data analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amy Mahanes</name_or_title>
      <organization>Ethicon Endo-Surgery, Inc.</organization>
      <phone>513-337-8366</phone>
      <email>amahanes@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

